Cytokinetics (CYTK) Stock Forecast & Price Target

$54.09

-1.84 (-3.29%)

(As of 09/6/2024 ET)

Cytokinetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for Cytokinetics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, and 11 have given a buy rating for CYTK.

Consensus Price Target

$80.67
49.13% Upside

High Forecast	$106.00
Average Forecast	$80.67
Low Forecast	$60.00

According to the 15 analysts' twelve-month price targets for Cytokinetics, the average price target is $80.67. The highest price target for CYTK is $106.00, while the lowest price target for CYTK is $60.00. The average price target represents a forecasted upside of 49.13% from the current price of $54.09.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	15 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$80.67	$77.06	$76.41	$58.21
Forecasted Upside	49.13% Upside	47.03% Upside	47.93% Upside	55.36% Upside

Get Cytokinetics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto 101 Media

Perfect Crypto Buying Opportunity for 50 Cents

When cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious Bank

Go here to get full details on this crypto now.

CYTK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYTK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cytokinetics Stock vs. The Competition

Type	Cytokinetics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	49.13% Upside	1,206.56% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$65.00 ➝ $71.00	+27.26%
9/4/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00 ➝ $78.00	+44.10%
9/3/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+61.38%
9/3/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00	+26.14%
8/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Choi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.80%
6/4/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$122.00 ➝ $92.00	+89.81%
Get the Latest News and Ratings for CYTK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.
5/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $70.00	+45.20%
5/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$70.00 ➝ $60.00	+20.53%
5/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$100.00 ➝ $95.00	+92.19%
5/23/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $70.00	+42.80%
5/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$107.00 ➝ $106.00	+65.08%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $99.00	+49.03%
1/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$61.00 ➝ $92.00	+8.49%
1/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$60.00 ➝ $90.00	+1.99%
10/9/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$59.00 ➝ $65.00	+112.42%
8/15/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/15/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%
8/15/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:53 PM ET.

CYTK Forecast - Frequently Asked Questions

What is Cytokinetics' forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Cytokinetics is $80.67, with a high forecast of $106.00 and a low forecast of $60.00.
Should I buy or sell Cytokinetics stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
Does Cytokinetics's stock price have much upside?: According to analysts, Cytokinetics's stock has a predicted upside of 41.00% based on their 12-month stock forecasts.
Has Cytokinetics been downgraded by Wall Street analysts recently?: Over the previous 90 days, Cytokinetics's stock had 1 downgrade by analysts.
What analysts cover Cytokinetics?: Cytokinetics has been rated by research analysts at HC Wainwright, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Cytokinetics more than its competitors?: Analysts like Cytokinetics less than other "medical" companies. The consensus rating score for Cytokinetics is 2.73 while the average consensus rating score for "medical" companies is 2.77. Learn more on how CYTK compares to other companies.